Why Provectus Biopharmaceuticals (PVCT) Stock Is Plunging Today

NEW YORK (TheStreet) -- Provectus Biopharmaceuticals  (PVCT) plunged Wednesday after the site amended its website homepage to call PV-10 an "investigational drug for cancer" after it had previously called it a "breakthrough cancer drug."

TheStreet's Adam Feuerstein posted an article with screenshots of the two homepage descriptions and he points out Provectus is supposed to get a response from the FDA this week about its request to grant PV-10 Breakthrough Therapy status for skin cancer. The company has said nothing thus far about the FDA's response.

Seeking Alpha also posted an extremely bearish article on Provectus on Wednesday.

Must Read: Provectus Disappears 'Breakthrough' Drug Claim on Web Site

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 18.15% to $2.21 at 12:08 p.m.

PVCT Chart

PVCT data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists